Oxford Glycosciences
Article Abstract:
Oxford Glycosciences specializes in proteins and their links with specific diseases. Credit Suisse First Boston notes the large number of patents held bythe company and rates its stocks a buy. Nomura rates the stocks a hold, and notes that roteomics technology may not bring in sufficient mney over the short term to justify a high stock price. Cazenove emphasizes the importance of patents, and rates the company's stocks a long-term buy. The collaborations between the company and major pharmaceutical concerns are important for the company's future.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Oxford GlycoSciences
Article Abstract:
Oxford GlycoSciences has a number of major research contracts, as well as more than 1,000 patents, though the company cannot easily be valued.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Oxford Glycosciences
Article Abstract:
Oxford Glycosciences has a large number of patents which could bring benefits if they are used for drug development.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
User Contributions:
Comment about this article or add new information about this topic: